You are here: Industry Insights > Intellia

News List

Intellia Therapeutics Announces Proposed Public Offering of Common Stock firstwordpharma
June 29, 2021
Intellia announced today that it has commenced an underwritten public offering of $400 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) .
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) firstwordpharma
June 28, 2021
NTLA and REGN today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company americanpharmaceuticalreview
June 23, 2021
Blackstone Life Sciences has committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH.
CRISPR therapies could be one of the most transformative in human history, says GlobalData europeanpharmaceuticalreview
March 17, 2021
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
CRISPR-based cancer therapies likely to be a disruptive technology in healthcare: GlobalData expresspharma
March 15, 2021
Three leading companies racing to bring CRISPR therapies to the clinic are CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine.
GEMoaB, Intellia Enter Cellular Immunotherapy Research Pact contractpharma
July 21, 2020
Will combine GEMoaB's RevCAR technology platform with Intellia's genome editing technologies to discover and develop allogeneic cellular immunotherapies.
Regeneron and Intellia to develop new haemophilia therapies pharmaceutical-technology
June 03, 2020
Regeneron Pharmaceuticals has expanded its ongoing partnership with Intellia Therapeutics for the development of therapies for haemophilia A and B.
News of Note—Seqirus, Fujifilm and more fiercepharma
August 17, 2017
A Fujifilm Diosynth partnership and flu vaccine effectiveness are among this week's news of note.